Adrenal Cortical Carcinoma (ACC) is a rare, aggressive malignancy arising from the cortex of the adrenal glands, which are responsible for producing essential hormones including cortisol, aldosterone, and androgens. This cancer can present as functional, in which the tumor secretes excess hormones causing clinical syndromes such as Cushings syndrome, virilization, hypertension, or electrolyte imbalances, or as non-functional, where hormone production remains normal and symptoms typically result from mass effect, such as abdominal pain, early satiety, or palpable abdominal mass. The staging of ACC is critical for guiding treatment and prognosis and is commonly assessed using the TNM system in combination with the European Network for the Study of Adrenal Tumors (ENSAT) classification. Stage I tumors are small (?5 cm) and confined entirely to the adrenal gland, without regional lymph node involvement or distant metastasis. Stage II tumors exceed 5 cm but remain localized to the adrenal gland, still without lymphatic or distant spread. Stage III is defined by local invasion into surrounding tissues, such as the kidney, liver, or major blood vessels, or the presence of regional lymph node metastases, indicating more advanced local disease. Stage IV represents the most advanced form, where the tumor has metastasized to distant organs, most commonly the liver, lungs, or bones, often resulting in systemic symptoms and a poorer prognosis. Due to the aggressive nature of ACC, early detection, accurate staging, and comprehensive evaluation of hormone activity are essential for determining the most appropriate surgical, medical, and adjunctive treatment strategies, as well as for improving patient survival outcomes.

Risk factors for Adrenal Cortical Carcinoma (ACC) include a combination of genetic, demographic, and environmental influences. Certain genetic conditions significantly increase susceptibility, such as Li-Fraumeni syndrome, Beckwith-Wiedemann syndrome, and Lynch syndrome, all of which are associated with mutations that predispose individuals to various cancers, including ACC. Female gender appears to carry a slightly higher risk, although the difference is modest. Age is also an important factor, with most cases occurring in young children under 5 years or in adults between 40 and 60 years, reflecting a bimodal age distribution. Environmental exposures, including smoking and contact with certain industrial chemicals, have been suggested as potential contributors to disease development, although these associations are less well established than genetic factors.

Symptoms of Adrenal Cortical Carcinoma (ACC) vary depending on whether the tumor is functional (hormone-producing) or non-functional. Functional tumors cause symptoms related to hormone overproduction. Excess cortisol leads to Cushings syndrome, characterized by rapid weight gain in the face and abdomen, high blood pressure, diabetes, muscle weakness, thin skin, and easy bruising. Overproduction of androgens (testosterone and DHEA) may cause women to develop facial hair, a deepened voice, and irregular menstrual cycles, while men are often asymptomatic. Excess estrogens can result in gynecomastia and loss of libido in men, and irregular menstrual cycles or postmenopausal bleeding in women. Overproduction of aldosterone leads to high blood pressure, low potassium levels, and muscle weakness. Non-functional tumors, which do not secrete hormones, typically present symptoms related to tumor growth, including abdominal or back pain, unexplained weight loss, and sometimes a palpable abdominal mass.

Diagnosis of Adrenal Cortical Carcinoma (ACC) involves a combination of imaging studies, hormonal evaluations, and, in select cases, tissue sampling to confirm the nature and extent of the tumor. Imaging tests such as CT scans and MRI are routinely used to determine the tumors size, location, and local invasion, while PET scans help identify distant metastases. Hormonal testing is essential for functional tumors and typically includes 24-hour urine collection and blood tests to measure levels of cortisol, aldosterone, androgens, and estrogens, which can indicate hormone overproduction. Biopsy, such as fine needle aspiration (FNA), is generally avoided before surgery due to the risk of spreading cancer cells, and is only performed in rare cases where the diagnosis remains uncertain and cannot be established by imaging and hormonal studies alone.

Treatment of Adrenal Cortical Carcinoma (ACC) depends on the stage of the disease, tumor functionality, and patient health, with surgery remaining the mainstay for localized tumors. Surgical removal via adrenalectomy, which completely excises the affected adrenal gland, is considered the primary treatment for Stage IIII tumors and offers the best chance for cure. For advanced disease or as adjuvant therapy to reduce recurrence risk after surgery, mitotane, an adrenal-specific chemotherapy drug, is commonly used. In more aggressive or metastatic cases, combination chemotherapy regimens such as mitotane with etoposide, doxorubicin, and cisplatin (EDP) may be administered. Radiation therapy can be applied postoperatively to lower the likelihood of local recurrence, particularly in cases with incomplete resection or high-risk features.Emerging targeted therapies and immunotherapies, including PD-1 inhibitors like pembrolizumab and nivolumab, are under research and clinical trials, offering potential future options for personalized treatment in advanced or resistant ACC.

Risk reduction for Adrenal Cortical Carcinoma (ACC) focuses on early identification of high-risk individuals and the adoption of preventive measures. Genetic screening is recommended for people with inherited cancer syndromes such as Li-Fraumeni or Beckwith-Wiedemann, which significantly increase the likelihood of developing ACC. Maintaining a healthy lifestyle, including a balanced diet and regular physical activity, may help support overall hormonal and metabolic health, although direct prevention of ACC through lifestyle alone is not established. Additionally, early detection through regular monitoring in high-risk patients is crucial, as it enables timely intervention, improves treatment outcomes, and may reduce disease-related complications.

Current research on Adrenal Cortical Carcinoma (ACC) focuses on targeted therapies against specific tumor mutations, immunotherapy trials to enhance the immune response, and genetic studies to understand tumor behavior and guide personalized treatment strategies.

1. What is Adrenal Cortical Carcinoma (ACC)? It is a rare and aggressive cancer originating in the outer layer (cortex) of the adrenal glands, which produce hormones such as cortisol, aldosterone, and androgens. 2. Is ACC curable? Yes, ACC can be curable if detected early and completely removed surgically, most commonly through adrenalectomy. 3. What are the symptoms of ACC? Symptoms vary by tumor type. Functional tumors cause hormonal imbalances, such as Cushings syndrome, virilization, gynecomastia, or high blood pressure. Non-functional tumors may cause abdominal or back pain, weight loss, or a palpable mass. 4. How is ACC diagnosed? Diagnosis involves imaging tests (CT, MRI, PET), hormonal evaluations (blood and 24-hour urine tests), and rarely biopsy, which is usually avoided before surgery due to the risk of cancer spread. 5. What are the treatment options for ACC? Treatment depends on stage and tumor behavior, including surgery (primary treatment), mitotane therapy, combination chemotherapy, radiation, and emerging targeted therapies and immunotherapy under research.